化疗联合过继免疫细胞治疗晚期非小细胞肺癌的临床研究  

Observation of Chemotherapy Combined with Cytokine-induced Killer Cells and Dendritic Cells in Patients with the Advanced Non-Small Cell Lung Cancer

作　　者：徐永茂[1] 徐冬云[1] 张南征[1] 陈复兴[1] 刘军权[1] 

机构地区：[1]解放军第九七医院,221004

出　　处：《实用癌症杂志》2010年第2期163-166,共4页The Practical Journal of Cancer

摘　　要：目的探讨化疗联合杀伤细胞(CIK细胞)和树突状细胞(DC)过继免疫治疗晚期非小细胞肺癌的临床疗效。方法78例中晚期非小细胞肺癌患者随机分成研究组38例(化疗+过继免疫治疗)与对照组40例(化疗),研究组采用NP方案联合CIK细胞和DC治疗,对照组采用NP方案化疗,观察两组临床疗效、毒副作用、患者生活存质量、免疫功能。结果研究组有效率(65.7%)明显高于对照组(40.0%、P<0.05),研究组TTP为5.3个月、MST为11.9个月(95%CI6.5～15.6个月),对照组TTP为4.6个月、MST为10.4个月(95%CI4.5～12.1个月),两组无显著性差异(P=0.12,P=0.15)。研究组患者生存质量及免疫功能明显高于对照组(P<0.05),而两组毒副作用无明显差别。结论采用化疗联合CIK细胞和DC过继免疫治疗晚期非小细胞肺癌,近期疗效较好,可以明显改善患者生活质量,延缓生存期。Objective To evaluate the effects of chemotherapy and Cytokine-induced killer （CIK） ceils and dendritic ceils（DC） therapy the advanced of non-small cell lung cancer （NSCLC）. Methods 78 patients with advanced NSCLC were randomized into study group （chemotherapy ＋ CIK ceils ＋ DCs, n = 38） and control group （chemotherapy alone, n = 40）. Patients in both groups received the NP chemotherapy,and patients in the study group also received CIK and DCs sequent/ally to chemotherapy. Results The response rate was 65.7% in the study group, which was significantly higher than that in the control group （P 〈 0.05, X2 = 4.22）. The time to tumor progress （TTP） and median survival time （MST） in the study group were 5.3 months and 11.9 months, respectively, which were not significantly different to that in the control group （4.6 and 10.6 months, P = 0.12 ,P = 0.15）. Quality of life and immunological function were significantly better in the study group than that in the control group. Toxicities were not significantly different in both groups. Conclusion Chemotherapy combined with sequential CIK cells and DCs might improve the treatment effects for patients with advanced NSCLC.

关 键 词：化疗 CIK细胞 树突状细胞 肺肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]